Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539929 · ClinicalTrials.gov registry record · Phase 2
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00539929 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 100 participants.
The verdict
NCT00539929, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis. Treatment duration is 8 weeks, followed by a 4-week period without treatment. Pharmacokinetic samples will be obtained pre-and post treatment.
Interventions
- DRUG Placebo
- DRUG E6201 0.005%
- DRUG E6201 0.01%
- DRUG E6201 0.03%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539929
The ClinicalTrials.gov registry entry for NCT00539929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00539929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539929 about?
NCT00539929 is a clinical study titled "Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis". This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis. Treatment duration is 8 weeks, followed by a 4-week period without treatment. Pharmacokinetic samples wil...
What is the current status of trial NCT00539929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-09. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00539929?
The interventions under investigation include: Placebo (DRUG), E6201 0.005% (DRUG), E6201 0.01% (DRUG), E6201 0.03% (DRUG).
Who is sponsoring clinical trial NCT00539929?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.